Role of Gene Variation in Effectiveness of Gleevec Treatment

Completed

Conditions studied: Cancer, Breast Cancer

In brief

This study will examine DNA from cancer patients previously treated with Gleevec to look for a variation (mutation) of the ABCG2 gene that may render the drug less effective in certain patients. Gleevec is used to treat chronic myeloid leukemia and gastrointestinal tumors. Although most patients respond to treatment, many with advanced disease develop resistance to the drug. It is thought that in some patients this resistance results from the action of a protein that causes Gleevec to be pumped out of the cells, reducing its usefulness. Patients enrolled in clinical trials of Gleevec at the National Cancer Institute and at other participating institutions are eligible for this study. DNA from patients' blood samples are analyzed for the ABCG2 gene and correlated with clinical data, such as the patient's age, race, disease state, weight, height, and body surface area. It will also look at the drug dose, how often the drug is given, the duration of treatment, side effects and other medications taken.

Key facts

Study ID

NCT00342056

Run by

National Cancer Institute (NCI)

People needed

100

Starts

2005-01-01

Expected to finish

2008-10-01

Last updated by the study team

2011-05-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Not applicable.

Where it is running

• Washington Hospital Center — Washington D.C., District of Columbia, United States
• Katholieke Universiteit Leuven, U Hospitals UZ Gasthuisberg — Leuven, Belgium

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.